EGFR/MDM2 signaling promotes NF-κB activation via PPARγ degradation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Dysregulated epidermal growth factor receptor (EGFR) is linked to cancer.
• Peroxisome proliferator-activated receptor γ (PPARγ) inhibits cancer progression.
• The interaction mechanism between EGFR and PPARγ is not fully understood.

Purpose of the Study:

• To elucidate the molecular mechanism by which EGFR interacts with and regulates PPARγ.
• To investigate the role of this interaction in cancer cell proliferation and sensitivity to chemotherapy.
• To explore the potential of targeting this pathway for cancer therapy.

Main Methods:

• Investigated EGFR-PPARγ interaction using molecular biology techniques.
• Assessed PPARγ phosphorylation, ubiquitination, and degradation.
• Analyzed the impact on nuclear factor-kappaB (NF-κB) signaling.
• Utilized PPARγ-Y74A mutant to validate findings.
• Examined clinical colonic cancer tissues for EGFR expression and PPARγ phosphorylation.

Main Results:

• Nuclear EGFR phosphorylates PPARγ at Tyr-74, leading to MDM2-mediated ubiquitination and degradation.
• PPARγ degradation by EGFR/MDM2 signaling enhances NF-κB/p65 accumulation and activation.
• PPARγ-Y74A mutant prevented degradation, suppressed proliferation, and increased chemosensitivity.
• Elevated nuclear p-PPARγ-Y74 and EGFR expression observed in colonic cancer tissues.

Conclusions:

• Nuclear EGFR promotes cancer cell proliferation by degrading PPARγ via the EGFR/MDM2/NF-κB pathway.
• This study reveals a novel mechanism linking EGFR signaling to PPARγ destruction.
• Targeting the nuclear EGFR-PPARγ interaction presents a promising therapeutic strategy for cancer treatment.